Obsidian Therapeutics, Inc.
18.68USD
-0.0500 (-0.27%)
Revenue
| (USD) | 2026 | 2027 |
|---|---|---|
| FY | 0.0 | 0.0 |
| Q1 | — | — |
| Q2 | 0.0 | — |
| Q3 | — | — |
| Q4 | 0.0 | — |
Revenue
| (USD) | 2026 | 2027 |
|---|---|---|
| FY | -1.00 | -2.13 |
| Q1 | — | — |
| Q2 | -.380 | — |
| Q3 | — | — |
| Q4 | -.410 | — |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.